Damora Therapeutics, Inc. Common Stock (DMRA) – What Are Researchers Saying About This Stock?

Shares of Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) have earned an average recommendation of “Buy” from the twelve brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $46.50.

Several brokerages have commented on DMRA. Jefferies Financial Group began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They issued a “buy” rating and a $50.00 price target for the company. Wall Street Zen upgraded shares of Damora Therapeutics, Inc. Common Stock from a “sell” rating to a “hold” rating in a research note on Sunday. TD Cowen raised Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, August 24th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a research report on Tuesday, July 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th.

Damora Therapeutics, Inc. Common Stock Stock Performance

NASDAQ DMRA opened at $18.43 on Thursday. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of -5.47 and a beta of 1.43. The firm has a 50 day simple moving average of $25.90 and a 200-day simple moving average of $25.82. Damora Therapeutics, Inc. Common Stock has a one year low of $4.95 and a one year high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last announced its earnings results on Monday, August 10th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.06. Equities analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.06 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Jennifer Jarrett purchased 12,500 shares of the business’s stock in a transaction on Friday, September 25th. The shares were bought at an average price of $20.23 per share, for a total transaction of $252,875.00. Following the acquisition, the chief executive officer directly owned 512,500 shares in the company, valued at $10,367,875. This trade represents a 2.50% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Braidwell LP purchased a new position in shares of Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $42,146,000. Seven Fleet Capital Management LP acquired a new position in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth about $7,398,000. Squarepoint Ops LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $303,000. Finally, Arizona State Retirement System purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $260,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

About Damora Therapeutics, Inc. Common Stock

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.